Page 84 - PRESENTATION

Combination Approaches

EV + Pembrolizumab

Patient Dose Escalation Cohort Dose Expansion Cohorts

Populatio
n Cohort D

Dose Escalation EV + cisplatin
EV + pembro Cohort A 1L Cohort G
Locally EV + pembro EV +

Advanced cis/carbo +
or cis-ineligible cis-ineligible Cohort E pembro
Metastatic 1L or 2L 1L EV + 1L

Urothelial carboplatin
Cancer 1L

(la/mUC)
Optional Optional
Cohort B Cohort F

EV + pembro EV +
2L gemcitabine
1L or 2L

Hoimes C, S ESMO 2019